Cargando…

Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay

BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Hideaki, Miyakawa, Kei, Ohtake, Norihisa, Go, Hirofumi, Yamaoka, Yutaro, Yajima, Satoshi, Shimada, Tomoko, Goto, Atsushi, Nakajima, Hideaki, Ryo, Akihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627865/
https://www.ncbi.nlm.nih.gov/pubmed/34857462
http://dx.doi.org/10.1016/j.jiac.2021.11.021
_version_ 1784606901624897536
author Kato, Hideaki
Miyakawa, Kei
Ohtake, Norihisa
Go, Hirofumi
Yamaoka, Yutaro
Yajima, Satoshi
Shimada, Tomoko
Goto, Atsushi
Nakajima, Hideaki
Ryo, Akihide
author_facet Kato, Hideaki
Miyakawa, Kei
Ohtake, Norihisa
Go, Hirofumi
Yamaoka, Yutaro
Yajima, Satoshi
Shimada, Tomoko
Goto, Atsushi
Nakajima, Hideaki
Ryo, Akihide
author_sort Kato, Hideaki
collection PubMed
description BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2. METHODS: We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers. RESULTS: The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r = 0.7535 in 4 weeks; r = 0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose. CONCLUSIONS: SP IgG index values were rised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain.
format Online
Article
Text
id pubmed-8627865
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86278652021-11-29 Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay Kato, Hideaki Miyakawa, Kei Ohtake, Norihisa Go, Hirofumi Yamaoka, Yutaro Yajima, Satoshi Shimada, Tomoko Goto, Atsushi Nakajima, Hideaki Ryo, Akihide J Infect Chemother Original Article BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2. METHODS: We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers. RESULTS: The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r = 0.7535 in 4 weeks; r = 0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose. CONCLUSIONS: SP IgG index values were rised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-02 2021-11-29 /pmc/articles/PMC8627865/ /pubmed/34857462 http://dx.doi.org/10.1016/j.jiac.2021.11.021 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Kato, Hideaki
Miyakawa, Kei
Ohtake, Norihisa
Go, Hirofumi
Yamaoka, Yutaro
Yajima, Satoshi
Shimada, Tomoko
Goto, Atsushi
Nakajima, Hideaki
Ryo, Akihide
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title_full Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title_fullStr Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title_full_unstemmed Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title_short Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
title_sort antibody titers against the alpha, beta, gamma, and delta variants of sars-cov-2 induced by bnt162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627865/
https://www.ncbi.nlm.nih.gov/pubmed/34857462
http://dx.doi.org/10.1016/j.jiac.2021.11.021
work_keys_str_mv AT katohideaki antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT miyakawakei antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT ohtakenorihisa antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT gohirofumi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT yamaokayutaro antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT yajimasatoshi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT shimadatomoko antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT gotoatsushi antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT nakajimahideaki antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay
AT ryoakihide antibodytitersagainstthealphabetagammaanddeltavariantsofsarscov2inducedbybnt162b2vaccinationmeasuredusingautomatedchemiluminescentenzymeimmunoassay